GSK plc reports

Company location
London
GSK plc has filed 6,835 SEC EDGAR filings since 12 Jan 2001

SEC filing history

Showing 1-25 of 1,000 matching filings.

Per page
25
Current page
1
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
24 Sep 2026
Reporting date
24 Sep 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
CERT File 001-15170

NYSE CERTIFICATION

Filing date
22 Sep 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
22 Sep 2026
Reporting date
22 Sep 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
8-A12B File 001-15170

8-A12B

Filing date
15 Sep 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

6-K

Filing date
15 Sep 2026
Reporting date
15 Sep 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

GSK TO ACQUIRE T CELL-ENGAGER FOR MULTIPLE MYELOMA

Filing date
15 Sep 2026
Reporting date
15 Sep 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

RIS-REZ POSITIVE PH 3 OS LUNG CANCER DATA IN CHINA

Filing date
14 Sep 2026
Reporting date
14 Sep 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

JIDEYTRO POSITIVE DATA FOR ROS1-POSITIVE NSCLC

Filing date
14 Sep 2026
Reporting date
14 Sep 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
11 Sep 2026
Reporting date
11 Sep 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
10 Sep 2026
Reporting date
10 Sep 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

JAPAN APPROVAL OF SHINGRIX IN A PREFILLED SYRINGE

Filing date
10 Sep 2026
Reporting date
10 Sep 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
09 Sep 2026
Reporting date
09 Sep 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
09 Sep 2026
Reporting date
09 Sep 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
FWP File 333-278205

FWP

Filing date
09 Sep 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
424B2 File 333-278205

424B2

Filing date
08 Sep 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

6-K

Filing date
08 Sep 2026
Reporting date
08 Sep 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

TOTAL VOTING RIGHTS

Filing date
01 Sep 2026
Reporting date
01 Sep 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

MRNA FLU VACCINE CANDIDATE TO ADVANCE TO PHASE III

Filing date
01 Sep 2026
Reporting date
01 Sep 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
26 Aug 2026
Reporting date
26 Aug 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
24 Aug 2026
Reporting date
24 Aug 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

FIRST GLOBAL APPROVAL FOR HIBSAGO IN JAPAN

Filing date
24 Aug 2026
Reporting date
24 Aug 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

US FDA TO REVIEW JEMPERLI FOR RECTAL CANCER

Filing date
24 Aug 2026
Reporting date
24 Aug 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
144 File 001-15170

144 filing

Filing date
20 Aug 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
18 Aug 2026
Reporting date
18 Aug 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .